GlassScriptPhysician profile
Richard Robinson
NPI 1336673656
$3,396.18
in general payments reported to CMS, 2019-2025
18 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $461 · 2024: $842 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,396.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $751.79 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $467.87 | 2024-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $405.59 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $326.68 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $290.34 | 2024-2025 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $220.12 | 2025 | Auvelity |
| Abbvie INC. | $206.64 | 2025 | |
| Vanda Pharmaceuticals INC. | $184.82 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $173.81 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $125.27 | 2023-2025 | Trintellix |
| Tris Pharma INC | $58.65 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $49.21 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $46.87 | 2023 | Azstarys |
| Almatica Pharma LLC | $20.61 | 2024 | Loreev Xr |
| Acadia Pharmaceuticals INC | $20.49 | 2025 | Nuplazid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $18.07 | 2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $15.80 | 2024 | |
| Noven Therapeutics, LLC | $13.55 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.